Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Relapsed/Refractory Immune Thrombocytopenia
NCT05599880Phase 2Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in immune thrombocytopenia (ITP), sponsored by Seoul National University Hospital. Started Jul 2023; status: recruiting.
02
Drugs
bortezomib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05599880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599880.